(IN BRIEF) The Conference Forum has announced the 9th annual Patients as Partners® Europe event, scheduled for May 20-21, 2025, at the Royal National Hotel in London. This event offers a platform for pharma R&D and patient advocacy to discuss … Read the full press release
Posted in France, Healthcare, Marketing, Pharma & Biotech, Science, Switzerland, United Kingdom
Tagged Alfred Samuels, AstraZeneca, Azafaros, Beyza Klein, Biotech, Biotechnology Conference, Boehringer Ingelheim, Bre Bugbee-Barrett, Catherine Coulouvrat MD, Chiesi Farmaceutici SpA, clinical development, clinical operations, clinical research, clinical research enterprise, clinical trial, clinical trials, Conference Forum, decentralized clinical trials, Gisela Linthorst, GSK, Harry Verbunt, HTA/Regulatory requirements, Johnson & Johnson Innovative Medicine, Lea-Isabelle Proulx PhD, life post-cancer diagnosis, Marisa Minetti, Medicine Development, Patient Advocacy, patient engagement, patient engagement in drug development, patient experience, Patient Recruitment, Patient Retention, Patients as Partners, Patients as Partners Europe, Peter DiBiaso, pharma, Pharmaceutical Conference, Regeneron, research and development, Roche, Royal National Hotel, Sanofi, Temi Olonisakin MD, The Conference Forum, Valerie Bowling
(IN BRIEF) Basilea Pharmaceutica Ltd announced that its antifungal drug, Cresemba® (isavuconazole), surpassed sales targets in Japan, triggering a CHF 1.2 million sales milestone payment from its partner Asahi Kasei Pharma. This achievement, reached in just the second year of … Read the full press release
Posted in Business, Financial, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Switzerland, Technology
Tagged Antifungal Drug, Asahi Kasei Pharma, Basilea Pharmaceutica Ltd, CHF 1.2 million, commercialization, Cresemba®, David Veitch, fungal infections, global sales, invasive fungal infections, Isavuconazole, Japan, market data, Market Growth, pharmaceutical industry, sales milestone
(IN BRIEF) SCHOTT Pharma’s AGM on February 4, 2025, revealed strong fiscal results for FY 2024, including exceeding revenue targets and a promotion to the MDAX. Shareholders approved all agenda items, including the appointment of Dr. Wolfram Carius to the … Read the full press release
Posted in Business, Financial, Germany, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged Annual General Meeting, appointment, corporate growth, dividend payout, Dr. Wolfram Carius, GLP-1 drugs, green financing, homecare solutions, INNOVATION, KPMG, leadership, Management, MDAX, mRNA, pharma industry, profitability, revenue guidance, SCHOTT Pharma, shareholder approval, shareholder engagement, Supervisory Board
(IN BRIEF) AstraZeneca’s Imfinzi (durvalumab) has received a positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for approval as a monotherapy to treat limited-stage small cell lung cancer (LS-SCLC) in patients whose disease … Read the full press release
Posted in Business, European Union, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged ADRIATIC Phase III trial, AstraZeneca, CHMP, disease progression, durvalumab, EMA, European Medicines Agency, hazard ratio, Imfinzi, immunotherapy, limited-stage small cell lung cancer, LS-SCLC, monotherapy, overall survival, platinum-based chemoradiation therapy, progression-free survival, regulatory review, safety profile, Small cell lung cancer, Suresh Senan, survival outcomes, Susan Galbraith, The New England Journal of Medicine, treatment approval
(IN BRIEF) The University of St.Gallen and ETH Zurich have partnered to establish the “ETH-HSG Manufacturing Alliance,” aimed at boosting the competitiveness of Swiss industry and nurturing young talent. The alliance is supported by 13 leading industrial partners, including Roche, … Read the full press release
Posted in Business, Education, Financial, Industrial, Investment, Management, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged artificial intelligence, artnership, Circle of Scholars, doctoral students, Endress+Hauser Flowtec, ETH Zurich, ETH-HSG Manufacturing Alliance, Givaudan, Johnson & Johnson Innovative Medicine, Leila Schwery, Lindt & Sprüngli, manufacturing innovation, Nestlé, Novartis, Operational Excellence, Peter Hagmann, Roche, Schindler, Schneider Electric, SFS Group, SHL Medical, sustainable business practices, Swiss industry, Swiss Manufacturing Survey 2024, Takeda, talent development, University of St.Gallen, VAT Group
(IN BRIEF) Sandoz has announced the retirement of Francisco Ballester, President of Region International, after 34 years of service, effective March 1, 2025. Francisco has been instrumental in expanding business growth and patient access in markets outside North America and … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged appointment, biosimilars, Business Growth, Chief Executive Officer, commercial strategy, Country President, Francisco Ballester, generics, Global Platform Head, Health Management and Policy Advisory Council, leadership, M&A, Miami Herbert Business School, patient access, Peter Stenico, Pro Generika, Region International, retirement, Richard Saynor, Sandoz, Sandoz Austria, Sandoz Executive Committee
(IN BRIEF) Krka achieved a score of 56 out of 100 in the 2024 S&P Global Corporate Sustainability Assessment, ranking the company among the top 10% of pharmaceutical firms. This marks an improvement over the previous year’s performance and highlights … Read the full press release
Posted in Awards, Business, Environment, Financial, Industrial, Investment, Management, News, Pharma & Biotech, Science, Slovenia, Technology
Tagged Awards, business ethics, environmental protection, ESG, good manufacturing practice, Governance, health and well-being, integrity, Krka, leadership, patient care, pharmaceutical industry, quality medicines, S&P Global Corporate Sustainability Assessment, social responsibility, sustainability, transparent operations
(IN BRIEF) Sanofi has announced the acquisition of 2.3% of its shares from L’Oréal, a long-standing shareholder, as part of its ongoing share buyback program. The transaction, valued at €3 billion, reflects Sanofi’s commitment to creating sustainable value for shareholders. … Read the full press release
Posted in Business, Financial, France, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged Autorité des Marchés Financiers, capital allocation policy, Chief Financial Officer, Earnings per share, Finexsi, François Roger, French Commercial Code, independent expert, L’Oréal, off-market block trade, Olivier Courau, Olivier Peronnet, partnership, related-party agreement, Sanofi, Share Buyback Program, share repurchase, Shareholder Value, transaction fairness, voting rights
(IN BRIEF) Roche has announced that the FDA has expanded the approval of its PATHWAY® HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test to identify HER2-ultralow status in HR-positive, HER2-negative metastatic breast cancer patients. This new approval offers a potential treatment … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Switzerland, Technology
Tagged breast cancer, DESTINY-Breast06 trial, diagnostic solutions, Enhertu, FDA, FDA approval, HER2-Low, HER2-targeted therapy, HER2-Ultralow, HR-positive, metastatic breast cancer, PATHWAY HER2, Personalized Treatment, Roche, treatment options
(IN BRIEF) ViiV Healthcare has secured European Commission approval for its long-acting HIV treatment, Vocabria + Rekambys, for adolescents aged 12 and older. This approval offers a significant advancement in HIV care, providing an injectable treatment option that reduces the … Read the full press release
Posted in Business, European Union, Financial, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged adolescents, clinical trial, European Commission, GSK, Healthcare Innovation, HIV care, HIV treatment, HIV treatment options, long-acting injections, MOCHA study, partnership, Rekambys, ViiV Healthcare, Vocabria
(IN BRIEF) Sarclisa (isatuximab) has been approved in China for use in combination with the VRd regimen to treat newly diagnosed multiple myeloma patients who are ineligible for autologous stem cell transplant. The approval is based on positive results from … Read the full press release
Posted in Business, Financial, France, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology
Tagged Approval, cancer treatment, CHINA, clinical trials, EU, FDA, global health, IMROZ study, isatuximab, Japan, Multiple Myeloma, Multiple Myeloma Treatment, new approvals, NMPA, oncology, Sanofi, Sarclisa, transplant-ineligible, VRd
(IN BRIEF) GSK has announced that the European Medicines Agency (EMA) has accepted its regulatory application for a prefilled syringe presentation of Shingrix, its recombinant zoster vaccine (RZV) for preventing shingles. This new presentation simplifies administration for healthcare providers by … Read the full press release
Posted in Business, Healthcare, Pharma & Biotech, United Kingdom
Tagged adult immunisation, adult vaccination, EMA, European Medicines Agency, European Union, FDA, GSK, healthcare professionals, herpes zoster, herpes zoster prevention, liquid adjuvant, lyophilised antigen, post-herpetic neuralgia, post-herpetic neuralgia prevention, Prefilled Syringe, Recombinant Zoster Vaccine, reconstitution, regulatory application, RZV, Shingles, Shingrix, submission, U.S. FDA, vaccination, vaccine
(IN BRIEF) GSK and the University of Oxford have launched the GSK-Oxford Cancer Immuno-Prevention Programme, a new research initiative focused on cancer prevention through vaccination. GSK is investing up to £50 million to explore how precancerous cells develop into cancer, … Read the full press release
Posted in Education, Healthcare, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Cancer Prevention, cancer vaccines, clinical trials, early-stage cancer, GSK, GSK-Oxford Cancer Immuno-Prevention Programme, GSK’s immune system expertise, immune system, immuno-oncology, Institute of Molecular and Computational Medicine, neoantigen sequencing, neoantigens, Peter Kyle, precancer biology, Professor Irene Tracey, targeted therapies, Tony Wood, translational research, tumor-specific proteins, University of Oxford, vaccination, vaccinology
(IN BRIEF) Roche has reported positive results from the second year of the EMBARK Phase III trial of Elevidys (delandistrogene moxeparvovec), the first approved gene therapy for Duchenne muscular dystrophy (DMD). The results showed statistically significant and clinically meaningful improvements … Read the full press release
Posted in Healthcare, Pharma & Biotech, Science, Technology
Tagged 10-meter walk/run, 10MWR, clinical data, clinical efficacy, crossover group, delandistrogene moxeparvovec, disease-modifying treatment, Duchenne muscular dystrophy, Elevidys, EMBARK trial, external control group, functional improvements, gene therapy, micro-dystrophin, motor function, muscle biopsies, muscle function preservation, muscle pathology, North Star Ambulatory Assessment, NSAA, Phase III study, regulatory approvals, Roche, safety profile, Sarepta Therapeutics, Time to Rise, TTR
(IN BRIEF) Evotec, Yonsei University, and Zymedi have been awarded a US$ 4.5 million grant from the Korea Institute of Advanced Technology (KIAT) to develop first-in-class biologic therapies for lung diseases, specifically asthma and idiopathic pulmonary fibrosis (IPF). The project … Read the full press release
Posted in Artificial Intelligence (AI), Business, Education, Financial, Germany, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged anti-fibrotic antibodies, anti-inflammatory antibodies, antibody development, asthma, biologic therapies, disease-causing enzymes, Evotec, fibrosis, idiopathic pulmonary fibrosis, IPF, KIAT, Korea Institute of Advanced Technology, lung diseases, novel mechanism-of-action, novel therapies, partnership, preclinical R&D, Sunghoon Kim, therapeutic antibodies, Thomas Hanke, tRNA synthetases, unmet medical needs, US$ 4.5 million grant, Yonsei University, Zymedi
(IN BRIEF) Sanofi’s Sarclisa has been approved by the European Union as the first anti-CD38 therapy in combination with VRd to treat adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. This approval is … Read the full press release
Posted in Business, European Union, Financial, France, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology
Tagged CD38 monoclonal antibody, clinical development, clinical trials, European Union approval, FDA approval, hematologic malignancies, immunoscience, isatuximab, Multiple Myeloma, NDMM, oncology, orphan drug exclusivity, Sanofi, Sarclisa, transplant-ineligible, treatment breakthrough, VRd
(IN BRIEF) SGS has acquired RTI Laboratories, a leading environmental and materials testing service provider in Detroit, Michigan. The acquisition expands SGS’s capabilities in PFAS analysis and materials testing while enhancing its regional presence in the Midwest. The move supports … Read the full press release
Posted in Business, Environment, Financial, Government, Industrial, Infrastructure & Utilities, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Switzerland, Technology
Tagged acquisition, alloy chemistry, Department of Defense, environmental testing, failure analysis, Marcus Maguire, materials testing, metallurgical testing, Michigan, North America, partnership, PFAS analysis, RTI Laboratories, SGS, SGS North America, Strategy 27, sustainability
(IN BRIEF) AstraZeneca’s Calquence (acalabrutinib) has been approved by the U.S. FDA for the first-line treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous hematopoietic stem cell transplantation. The approval is based on … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged acalabrutinib, AstraZeneca, autologous hematopoietic stem cell transplantation, bendamustine, blood cancers, Bruton’s tyrosine kinase, BTK inhibitor, Calquence, chemoimmunotherapy, COVID-19, Dave Fredrickson, ECHO Phase III trial, FDA, global regulatory review, international markets, Lymphoma Research Foundation, mantle cell lymphoma, MCL, Meghan Gutierrez, Michael Wang, oncology, PFS, progression-free survival, Project Orbis, regulatory submission, rituximab, safety profile, U.S. approval
(IN BRIEF) A new study from the University of Bristol has challenged the long-standing belief that waking up triggers a spike in cortisol, the body’s stress hormone. Published in Proceedings of the Royal Society B, the research shows that cortisol … Read the full press release
Posted in Business, Education, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged automated sampling system, BBSRC, Biotechnology and Biological Sciences Research Council, CAR, chronic fatigue syndrome, circadian rhythm, cortisol, cortisol awakening response, cortisol dynamics, cortisol secretion, depression, Dr. Thomas Upton, EU Horizon 2020, medical school, Proceedings of the Royal Society B, Professor Marcus Munafò, Professor Stafford Lightman, PTSD, research findings, Sleep, sleep disorders, stress hormone, Ultradian grant, University of Bristol
(IN BRIEF) AstraZeneca and Daiichi Sankyo’s Biologics License Application (BLA) for datopotamab deruxtecan has been accepted by the U.S. FDA for treating advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) in patients who have previously received systemic therapies. The … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged advanced NSCLC, antibody-drug conjugate, AstraZeneca, Biologics License Application, BLA, breakthrough therapy designation, Daiichi Sankyo, datopotamab deruxtecan, drug approval, EGFR-mutated, EGFR-tyrosine kinase inhibitors, FDA, metastatic NSCLC, non-small cell lung cancer, NSCLC, objective response rate, oncology, partnership, Phase III Trials, Priority Review, safety profile, systemic therapies, TROP2-directed, TROPION-Lung01, TROPION-Lung05, TROPION-Lung14, TROPION-Lung15
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?